Director’s report and financial statements for the year ended 30th June 2017. (more…)
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 19 October 2017 of the following transactions in its ordinary shares of 5 pence each (“Ordinary Shares”)
(more…)
TR-1: Notification of major interest in shares. (more…)
TR-1: Notification of major interest in shares. (more…)
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, announces a trading update.
(more…)
TR-1: Notification of major interest in shares. (more…)
The Board has become aware of the launch of a new test by Siemens for troponin, a key biomarker used in heart attack diagnostics. (more…)
TR-1: Notification of major interest in shares. (more…)
TR-1: Notification of major interest in shares. (more…)